Neurovive Pharmaceutical AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.05.17	NeuroVive Pharmaceutical AB Interim Report January - March 2017 (PR Newswire)
18.05.17	NeuroVive Pharmaceutical AB Interim Report January - March 2017 (PR Newswire)
02.05.17	NeuroVive Invitation to Conference Call and Web Cast on in-licensing Agreement With Yungjin Pharm (PR Newswire)
02.05.17	NeuroVive Invitation to Conference Call and Web Cast on in-licensing Agreement With Yungjin Pharm (PR Newswire)
02.05.17	NeuroVive Invitation to Conference Call and Web Cast on in-licensing Agreement With Yungjin Pharm (PR Newswire)
02.05.17	NeuroVive in-licenses a Genetic Mitochondrial Disease Clinical Stage Project From Yungjin Pharm (PR Newswire)
20.04.17	NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects (PR Newswire)
20.04.17	NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects (PR Newswire)
20.04.17	NeuroVive Presents Preclinical Findings of NV556 in NASH Showing Confirmatory Anti-fibrotic Effects (PR Newswire)
05.04.17	NeuroVive's Lead NASH Project to be Presented at The International Liver Congress(TM) (PR Newswire)
05.04.17	NeuroVive's Lead NASH Project to be Presented at The International Liver Congress™ (PR Newswire)
05.04.17	NeuroVive's Lead NASH Project to be Presented at The International Liver Congress™ (PR Newswire)
31.03.17	Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) (PR Newswire)
31.03.17	Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) (PR Newswire)
31.03.17	Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ) (PR Newswire)
23.03.17	NeuroVive Pharmaceutical AB Publishes 2016 Annual Report (PR Newswire)
23.03.17	Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (PR Newswire)
23.03.17	NeuroVive Pharmaceutical AB Publishes 2016 Annual Report (PR Newswire)
23.03.17	NeuroVive Pharmaceutical AB Publishes 2016 Annual Report (PR Newswire)
23.03.17	Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB (PR Newswire)
22.02.17	NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma (PR Newswire)
22.02.17	NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma (PR Newswire)
22.02.17	NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma (PR Newswire)
21.02.17	NeuroVive Pharmaceutical AB Year End Report January - December 2016 (PR Newswire)
21.02.17	NeuroVive Pharmaceutical AB Year End Report January - December 2016 (PR Newswire)
21.02.17	NeuroVive Pharmaceutical AB Year End Report January - December 2016 (PR Newswire)
02.02.17	NeuroVive's new Generation of Sanglifehrin-based Compounds Demonstrate Potent Inhibitory Effects on Human Hepatocellular Cancer Cells (PR Newswire)
25.01.17	NeuroVive Redirects Research Resources From Asian Subsidiary to Parent (PR Newswire)
25.01.17	NeuroVive Redirects Research Resources From Asian Subsidiary to Parent (PR Newswire)
25.01.17	NeuroVive Redirects Research Resources From Asian Subsidiary to Parent (PR Newswire)
23.01.17	NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader (PR Newswire)
23.01.17	NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader (PR Newswire)
19.01.17	NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit (PR Newswire)
19.01.17	NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit (PR Newswire)
19.01.17	NeuroVive Presents Positive Preclinical Data in Hepatocellular Cancer at HCC Summit (PR Newswire)
10.01.17	NeuroVive Signs Collaboration Agreement With Karolinska Institutet (PR Newswire)
10.01.17	NeuroVive Signs Collaboration Agreement With Karolinska Institutet (PR Newswire)
03.01.17	NeuroVive to Present at the 9th Annual Biotech Showcase Conference (PR Newswire)
03.01.17	NeuroVive to Present at the 9th Annual Biotech Showcase Conference (PR Newswire)
22.11.16	NeuroVive Pharmaceutical AB Interim Report January - September 2016 (Businesswire)
08.11.16	Neurovive Pharmaceutical: NeuroVive’s Recruitment of Michele Tavecchio Strengthens Its Research Organization (Businesswire)
01.11.16	Neurovive Pharmaceutical: NeuroVive Reports Positive Pre-Clinical Results in NASH (Businesswire)
26.10.16	NeuroVive Pharmaceutical AB: Annual General Meeting 2017 and Nomination Committee (Businesswire)
25.10.16	NeuroVive Pharmaceutical: NeuroVive Completes Closure of Lyon Subsidiary (Businesswire)
21.10.16	Neurovive Pharmaceutical: NeuroVive and Arbutus Sign Termination Agreement (Businesswire)
13.10.16	NeuroVive discontinues development of CicloMulsion for acute kidney injury (Businesswire)
07.09.16	Neurovive Pharmaceutical: NeuroVive to Present at the Rodman & Renshaw 18th Annual Global Investment Conference (Businesswire)
30.08.16	Neurovive Pharmaceutical: NeuroVive Announces That the Clinical Study CiPRICS Will Be Presented at the Swedish Thorax Meeting in October 2016 (Businesswire)
24.08.16	NeuroVive Pharmaceutical: NeuroVive’s Chief Operating Officer Jan Nilsson Leaves the Company (Businesswire)
18.08.16	NeuroVive Pharmaceutical - Interim Report January-June 2016 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Neurovive Pharmaceutical AB

Aktien Top/Flop

Meistgelesene Nachrichten